US NIH launches $215m Partnership for Accelerating Cancer Therapies

The US National Institutes of Health (NIH), along with 11 biopharmaceutical companies, has launched a $215m five-year public-private research collaboration to advance new cancer immunotherapy strategies for more patients.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news

Related Links:

Roche already owns a majority stake in Foundation Medicine, but now the Swiss company wants to buy the rest of the genomic diagnostics company, and it is willing to pay a pretty penny to do so. Roche agreed to pay $137 a share to buy the rest of Cambridge, MA-based Foundation Medicine, a $2.4 billion transaction that values the company at $5.3 billion. The offer price represents a 29% premium over Foundation Medicine's closing stock price Monday. The deal is expected to close during the second half of the year. The deal marks a turning point in Roche's relationship with Foundation Medicine, which dates back to January...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news
AbstractImmune checkpoint antagonists (CTLA-4 and PD-1/PD-L1) and CAR T-cell therapies generate unparalleled durable responses in several cancers and have firmly established immunotherapy as a new pillar of cancer therapy. To extend the impact of immunotherapy to more patients and a broader range of cancers, targeting additional mechanisms of tumor immune evasion will be critical. Adenosine signaling has emerged as a key metabolic pathway that regulates tumor immunity. Adenosine is an immunosuppressive metabolite produced at high levels within the tumor microenvironment. Hypoxia, high cell turnover, and expression of CD39 ...
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
This study sought to develop a simple nanoparticle-based approach to enhance the efficiency and tolerability of lipopolysaccharide (LPS), a potent ligand of Toll-like Receptor 4 (TLR4), for immunotherapy in cancer. Despite holding promise within this context, the strong pro-inflammatory properties of LPS also account for its low tolerability given localized and systemic side effects, which restrict the administrable dosage. Herein, we investigated the effect of LPS decoration as a surface-active molecule on a polymeric matrix upon its efficiency and tolerability. The LPS-decorated nanoparticles (LPS-NP) were about 150&thin...
Source: Drug Delivery - Category: Drugs & Pharmacology Tags: Drug Deliv Source Type: research
Immune-based therapy has emerged as a paradigm shift in cancer therapy with dramatic responses observed in previously incurable disease. Cancer vaccines are being developed to disrupt tumor-associated tolerance and activate and selectively expand tumor-specific lymphocytes within the native effector cell repertoire while maintaining immune-regulatory protection against autoimmunity. Although individual antigen approaches result in immune response with a suggestion of clinical effect in some settings, broader efficacy may be dependent on presentation of multiple antigens that capture clonal diversity presented in the contex...
Source: Blood - Category: Hematology Authors: Tags: Immunobiology and Immunotherapy, Review Articles, Review Series, Clinical Trials and Observations Source Type: research
COPENHAGEN, Denmark, June 11, 2018 -- (Healthcare Sales &Marketing Network) -- IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies, based on its proprietary T-win technology, today announced th... Biopharmaceuticals, Oncology, Personnel IO Biotech, T-Win, immunotherapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
CONCLUSION: ICOS/ICOS-L signal pathway has the potential to improve cancer treatment. However, studies in other models are needed to understand whether inhibition of ICOS expression or the blockage of its co-stimulation could be a potential therapeutic target or adjuvant treatment for immunotherapy. PMID: 29879883 [PubMed - as supplied by publisher]
Source: Current Protein and Peptide Science - Category: Biochemistry Authors: Tags: Curr Protein Pept Sci Source Type: research
AbstractBackgroundThe clinical efficacy observed with inhibitors of programed cell death 1/programed cell death ligand 1 (PD-L1/PD-1) in cancer therapy has prompted studies to characterize the immune response in several tumor types, including lung cancer. However, the immunological profile of non –small cell lung carcinoma (NSCLC) treated with neoadjuvant chemotherapy (NCT) is not yet fully characterized, and it may be therapeutically important. The aim of this retrospective study was to characterize and quantify PD-L1/PD-1 expression and tumor-associated immune cells (TAICs) in surgically resected NSCLCs from patien...
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
In conclusion, EM-L2 displaying phage particles could be deemed as an encouraging strategy in contemporary cancer immunotherapy. PMID: 29908541 [PubMed - in process]
Source: Iranian Journal of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Iran J Allergy Asthma Immunol Source Type: research
Conclusions: Early favorable signs of FDG-PET parameters may vary among diseases with immune checkpoint inhibitors. Mean FDG uptake was elevated in several immune-related organs at the early restaging scan. Among them, elevated FDG accumulation in thyroid might be a candidate sign of monitoring effectiveness of immunotherapy observed earlier than immune-related lymphadenopathy. Relationship between % change () of PET parameters and patients outcome% chage (Î") of PET parametersMalignant melanoma(Odds, 95%CI, p)Malignant lymphoma (Odds, 95%CI, p)Renal cell carcinoma (Odds, 95%CI, p)Î&quo...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Other Solid Tumors Source Type: research
Conclusions In this study, we have developed NK cell-based theranostic platforms using radiolabeled and gold coated iron oxide nanoparticles, and demonstrated that PET/MRI/PA multimodal imaging and synergistic therapy by adoptive immunotherapy and NIR light-induced phototherapy therapy. This multimodal theranosis based on NK cells paves the way for the rational design of immuno-plasmonic theranostic platform. References 1. Zhigang Tian et al., "NK cell-based immunotherapy for malignant diseases", Cellular &Molecular Immunology, 2013, 10, 230-252. 2. Heike E. Daldrup-Link et al., "Monitoring of Natural Ki...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Novel Multimodality and Nonradioactive Probes Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Immunotherapy | National Institutes of Health (NIH) | Partnerships | Pharmaceuticals